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Background: Although some studies mainly from Taiwan, Bangladesh and the United States, have suggested a
consistent dose–response increase in the prevalence of hypertension with increasing arsenic exposure, the
association between chronic environmental arsenic exposure and the risk of hypertension is still inconclusive. Most
of the studies discussed the association from the point of view of arsenic concentration in drinking water or
cumulative arsenic exposure (CAE), few involved arsenic speciation into the discussion. In this cross-sectional study,
we evaluated the potential association between environmental arsenic exposure through drinking water and the
prevalence of hypertension by analyzing not only CAE but also urinary arsenic speciation, and provided data on
arsenic exposure and hypertension from mainland of China.
Methods: A cross-sectional study was conducted in one of the arsenic contaminated areas in the northwest of
China. Among a total of 1005 residents who voluntarily participated in the study, 604 of eligible subjects were
confirmed and interviewed door to door. Standing height, body weight, and blood pressure were measured. First
void urine was collected and measured for the concentration of urinary arsenic speciation. CAE was calculated in a
subpopulation of 360 subjects with detailed water consumption history. The association between urinary arsenic
speciation, CAE and the risk of hypertension were analyzed by multiple logistic regressions.
Results: We found that the levels of urinary arsenic species of inorganic arsenic (iAs), monomethylated arsenic (MMA),
dimethylated arsenic (DMA) and total arsenic (tAs) were significantly correlated with systolic or pulse blood pressure. A
positive relationship was found between the highest tertile of CAE and hypertension in a dose-dependent manner.
Subjects with higher concentration of urinary MMA or lower percentage of DMA tended to be liable to suffer from
hypertension. A significant increasing trend of the risk of hypertension with increasing tertiles of MMA concentration
was also observed in the logistic regression models both before and after adjustment for confounders.
Conclusions: Our findings suggested that arsenic exposure, especially high level of CAE, was positively associated with
the prevalence of hypertension, and that higher concentration of urinary MMA might be related to the increased
susceptibility to hypertension.
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Arsenic is a toxic metalloid element which is present in
the air, water and soil in both organic and inorganic
forms. The main source of environmental exposure to in-
organic arsenic (iAs) in humans is drinking water. The
World Health Organization (WHO) recently changed the
acceptable level of arsenic in drinking water to 0.01 mg/L.
However, many countries have kept the standard of
0.05 mg/L which was established in 1975. Among the
environmental exposures, arsenic contaminated drinking
water has been a major public health problem throughout
the world [1,2]. Millions of people around the world, such
as Bangladesh, China, India, Cambodia, Argentina and
Mexico, are being exposed to high level of arsenic through
drinking water and facing serious health hazard of arsenic-
related diseases [3].
In human, iAs is mainly metabolized enzymatically and
non-enzymatically in liver into monomethylated arsenic
(MMA) and dimethylated arsenic (DMA), which are then
rapidly excreted into the urine [4,5]. Methylation was
previously considered as a detoxification mechanism [6],
however, recent studies have identified that the intermedi-
ate metabolites of arsenic methylation, especially trivalent
MMA (MMAIII), are far more toxic than the inorganic
arsenic compounds [7,8]. Urinary arsenic speciation of
iAs, MMA, and DMA, is usually used as the indicator for
arsenic metabolism [9].
The association between the increased prevalence of
hypertension and the long-term arsenic exposure through
drinking water was first reported among the residents liv-
ing in the endemic arsenic poisoning villages of Taiwan in
1995 [10]. Then, epidemiological researches from Taiwan,
Bangladesh and the United States continuously reported
the evidences that individuals chronically exposed to ar-
senic through drinking water might be at higher risk of
developing hypertension compared to people unexposed,
and that the effects were dose-dependent [11-14].
Recently, a Meta-analysis on the association between
chronic arsenic exposure through drinking water and the
prevalence of hypertension which included 8 relevant
cross-sectional and cohort studies suggested that existing
human data provided limited support for an association
between arsenic and hypertension. It is still inconclusive
although arsenic is possibly associated with hypertension
[15]. While another systematic review that evaluated the
relationship between arsenic exposure and hypertension
end points by Meta-analysis from 11 cross-sectional stud-
ies (including 2 studies not exposed to arsenic through
drinking water) identified an association between arsenic
exposure and the prevalence of hypertension, but found
limited interpretations of a causal effect of environmental
arsenic on hypertension [16]. Due to the widespread ar-
senic exposure through drinking water in the world,
even a small possible association between arsenic andhypertension might lead to a large number of cases and
heavy burden of diseases caused by hypertension. Apart
from Taiwan, it is estimated that nearly millions of people
are being exposed to high level of arsenic (beyond the na-
tional standard of 0.05 mg/L) through drinking water in
the mainland of China, and tens of thousands of them are
suffering from arsenic-related diseases [17]. However, data
from China on the relationship between arsenic expos-
ure through contaminated drinking water and hyper-
tension is scarce. In this research, we conducted a
cross-sectional study in a county of Shanxi province, one
of the arsenic contaminated areas in China, to evaluate the
potential association between environmental arsenic ex-
posure through drinking water and the prevalence of
hypertension by analyzing urinary arsenic speciation and
cumulative arsenic exposure (CAE), with emphasis on the
association between arsenic speciation and hypertension,
which has been rarely discussed up to now.
Methods
Study subjects
This study was conducted in Shanyin county of Shanxi
province, one of the serious arsenic contaminated areas
found in the 1980s, which locates in the northwest of
China. Drinking water supply system in this region was
dependent on tube wells. Arsenic concentration ranged
from 0 to 0.65 mg/L according to the report of local
public health government. Since northwest of China is a
multinational area, only residents of Han nationality
(accounts for 80 percent of the residents) were recruited
so as to decrease the potential effects of gene poly-
morphism on the metabolism of arsenic methylation.
Besides, residents living in the study county more than
10 years were considered as eligible subjects. Residents
who took seafood in the past one week before the study
were excluded. Among a total of 1005 residents who vol-
untarily participated in the study, 604 of eligible subjects
were confirmed, and interviewed door to door. Stan-
dardized personal interview based on a structured ques-
tionnaire were carried out by well-trained interviewers.
Information obtained from the interview included water
consumption history, life style of cigarette smoking and
alcohol consumption, medical history, family history of
hypertension, diabetes, and other cardiovascular diseases,
and other information such as socioeconomic status,
demographic characteristics, and dietary habit. Compre-
hensive physical examination of residents recruited was
completed by experienced physicians. Standing height and
body weight were measured with a rigid vertical height
measurement and a standard medical balance scale, with
subjects not wearing shoes and in light clothes. Both inter-
viewers and physicians were blind to the arsenic con-
centration to which subjects were exposed until all the
interviews and physical examinations were completed.
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of China Medical University, and followed by the proce-
dures of the institutional guidelines. All of the residents
who participated in the study read and signed informed
consent.
Blood pressure measurements and diagnosis of
hypertension
According to the protocol recommended by the WHO
[18], blood pressure was measured three times with a
mercury sphygmomanometer in sitting position after
rest and relaxation for at least 15 minutes. Systolic blood
pressure and diastolic blood pressure were defined at
the first and fifth KorotKoff sounds, respectively. The
lowest value was taken as the proper value for this study.
Subjects who were found with elevated blood pressure
were rechecked for another two measurements a few
days later to validate the finding of hypertension (once
per visit). Hypertension was defined in this study as a
systolic blood pressure ≥ 140 mm Hg, a diastolic blood
pressure ≥ 90 mm Hg, or a history of hypertension
under regular treatment with antihypertensive agents.
Arsenic exposure measurements
Among the total 604 eligible subjects, 360 subjects pro-
vided detailed residential history and arsenic concentra-
tion in the wells which they used in each of the residential
duration. Since arsenic concentration was detected and
reported to the family by the local public health govern-
ment, it was considered as reliable in this study. CAE
was calculated for each subject in the subpopulation
with detailed water consumption history (n = 360). CAE
in mg/L-year was defined as ∑(Ci×Di), where Ci is the
arsenic concentration in mg/L in the tube wells which
the subjects used in that residential duration, and Di in
years is the duration of water consumption. CAE was
not calculated in 244 out of the 604 subjects due to un-
clear arsenic concentration or obscure memories of the
residential history.
Urine collection and arsenic speciation measurements
The midstream of the first void urine was collected, kept
on ice, immediately transferred to Centre for Disease
Control and Prevention of Shanyin County, and stored
at -20 centigrade. Samples then were transported on dry
ice to the Laboratory of Arsenic Analysis in China Medical
University, stored at -80 centigrade, and finally measured
for urinary arsenic speciation within 3 months.
Measurement of arsenic speciation was performed as
described previously [19]. Briefly, 1ml urine was digested
with 2 M NaOH at 95 centigrade for 3 hours. The samples
were stirred with a magnetic stirrer once every 30 minutes.
Then the treated samples were diluted to 10 ml. iAs,
MMA and DMA were measured by atomic absorptionspectrophotometer (AA6800, Shimadzu, Japan) with an ar-
senic speciation pretreatment system (ASA-2SP, Shimadzu,
Japan). Aliquot samples were used for each assay. Arsenic
speciation was based on the well-established hydride gen-
eration of volatile arsines, followed by cryogenic separation
in liquid nitrogen. The detection limit of each of the three
arsenicals (iAs, MMA, DMA) was 1 ng, and the coefficient
of variation was < 5%. The standard reference materials
used were iAs standard of 1000 mg/L from the National
Center for Standard Reference Materials (Beijing, China)
and a mixed arsenic standard of 1000 mg/L MMA and
DMA (Tri Chemical Laboratories Inc., Yamanashi, Japan).
Quality control for arsenic measurement included the
analysis of standard reference material of freeze-dried
urine for toxic metals (SRM2670, National Institute of
Standards and Technology [NIST], Gaithersburg, MD,
USA). The NIST-certified concentration value for ar-
senic was 480 ± 100 μg/L. The value measured in our
laboratory was 474 ± 20 μg/L. The value of each arsenic
species was finally adjusted by the concentration of
urinary creatinine (Cr). Total arsenic (tAs) concentra-
tion was calculated by summing the concentration of
iAs, MMA and DMA. Urinary arsenic speciation was
represented by urinary arsenic species (concentration of
iAs, MMA, DMA and tAs in μg/g Cr) and urinary ar-
senic percentage (proportions of iAs, MMA and DMA,
i.e. iAs%, MMA% and DMA%).
Statistical analysis
Data analysis was carried out by SPSS software (version
13.0, SPSS Inc., Chicago, IL, USA). The differences of
the categorical variables (gender, cigarette smoking and
alcohol consumption) and continuous variables (age, body
mass index (BMI), urinary arsenic species and percentage)
of the subjects between cases with and without hyperten-
sion were analyzed by chi square test and Student’s t test,
respectively. The relationship between urinary arsenic and
blood pressure was analyzed by the Pearson correlation
and partial correlation analysis. The associations between
urinary arsenic speciation and hypertension, CAE and
hypertension were analyzed by multiple logistic regression
to estimate the multivariate adjusted odds ratios (OR) and
95% confidence intervals (CI) for hypertension risk.
Results
Characteristics of the study population
Totally, 604 subjects including 255 males and 349 females
were included in this study. Characteristics of subjects with
and without hypertension with regard to gender, cigarette
smoking, alcohol consumption, age, BMI and urinary ar-
senic speciation were listed in Table 1. There were no dif-
ferences between cases with and without hypertension in
the distribution of gender, cigarette smoking and alcohol
consumption. The average age, BMI, and urinary arsenic
Table 1 Characteristics of subjects with or without hypertension with regard to gender, cigarette smoking, alcohol





Male 182 (41.7%) 73 (43.5%) 0.703
Female 254 (58.3%) 95 (56.5%)
Cigarette smokinga
Never 293 (67.2%) 119 (70.8%) 0.390
Current or former 143 (32.8%) 49 (29.2%)
Alcohol consumptiona
Never 336 (77.1%) 127 (75.6%) 0.702
Current or former 100 (22.9%) 41 (24.4%)
Ageb 46.37 (13.39) 57.58 (12.05) <0.001
BMI(kg/m2)b 22.53 (3.19) 24.65(3.89) <0.001
Urinary arsenic species (μg/g Cr)c
iAs 12.83 (10.96, 15.02) 17.11 (13.44, 21.79) 0.050
MMA 17.35 (15.33, 19.62) 23.75 (19.33, 29.18) 0.009
DMA 94.17 (85.50, 103.70) 123.95 (105.26, 145.96) 0.004
tAs 135.59 (123.03, 149.43) 178.33 (151.43, 210.01) 0.004
Urinary arsenic percentage (%)c
iAs 9.46 (8.62, 10.39) 9.60 (8.28, 11.12) 0.876
MMA 12.79 (12.06, 13.57) 13.32 (12.20, 14.55) 0.468
DMA 69.45 (67.52, 71.43) 69.51 (67.10, 72.00) 0.974
a Values are number (%).
b Values are mean (standard deviation).
c Values are geometric mean (95% confidence interval).
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hypertension were significantly higher than those of the
non-hypertension subjects, whereas urinary arsenic per-
centages of iAs, MMA and DMA were not significantly






iAs (μg/g Cr) 0.078 0.056
MMA (μg/g Cr) 0.128 0.002
DMA (μg/g Cr) 0.157 0.000





Data were based on log-transformed values.Relationship between urinary arsenic and blood pressure
As shown in Table 2, urinary arsenic species of MMA,
DMA and tAs were positively correlated with systolic or
pulse blood pressure with significant Pearson correlation
coefficients. A significant positive correlation was alsosure by bivariate correlation analysis






−0.015 0.706 0.130 0.001
0.016 0.689 0.177 0.000
0.034 0.400 0.204 0.000
0.027 0.510 0.203 0.000
−0.054 0.182 0.002 0.971
−0.011 0.793 0.035 0.391
0.027 0.507 −0.001 0.979
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blood pressure. No significant correlations were found
between urinary arsenic species and diastolic blood pres-
sure. Moreover, there were no significant correlations
between urinary arsenic percentage and blood pressure
(Table 2). After the adjustment for the variables of gen-
der, age, cigarette smoking, alcohol consumption and
BMI by partial correlation analysis, the results were
similar with those of the Pearson correlation analysis as
shown in Table 3. Urinary arsenic species of iAs, MMA,
DMA and tAs were significantly correlated with the level
of systolic or pulse blood pressure, while no significant
correlations were found between urinary arsenic species
and diastolic blood pressure, and between urinary ar-
senic percentage and blood pressure.
It is obvious that the more consumption of arsenic-
contaminated water, the higher levels of urinary arsenic
species. The findings of the correlations between urinary
arsenic and blood pressure, together with the evidence
that subjects with hypertension had significantly higher
levels of urinary arsenic species of iAs, MMA, DMA and
tAs than those without hypertension (Table 1) indicated
that higher levels of urinary arsenic species might be as-
sociated with the elevated blood pressure, especially sys-
tolic and pulse blood pressure.
Association between urinary arsenic speciation and the
risk of hypertension
The results of the association between urinary arsenic
speciation and hypertension by multiple logistic regres-
sion analysis were listed in Table 4. Subjects in the
highest tertile of urinary MMA concentration showed a
nearly 1.7 fold higher risk of hypertension than those in
the lowest tertile before the adjustment for the potential
confounders (OR: 1.776, 95% CI: 1.148, 2.746). There
was a significant trend of increasing risk of hypertension






iAs (μg/g Cr) 0.099 0.016
MMA (μg/g Cr) 0.098 0.016
DMA (μg/g Cr) 0.115 0.005





Data were based on log-transformed values.
Correlations were adjusted by gender, age, cigarette smoking, alcohol consumptionconcentration (p = 0.009). The significant association be-
tween urinary MMA concentration and hypertension in
the highest tertile, and the notable trend of increasing
risk of hypertension in corresponding to increasing level
of urinary MMA concentration still existed after the ad-
justment for the confounders. The OR (95% CI) of urin-
ary MMA concentration for the risk of hypertension was
1.693 (1.028, 2.787). The p value of the trend was 0.033.
The risk of hypertension was significantly higher in the
highest tertile of DMA concentration when compared
with that in the lowest tertile before the adjustment
(OR: 1.812, 95% CI: 1.166, 2.817), with a notable trend
of increasing hypertension risk along with increasing
level of urinary DMA concentration (p = 0.008). After
the adjustment, neither the association between urinary
DMA concentration and hypertension, nor the trend of
increasing hypertension risk along with increasing level
of urinary DMA concentration existed. Subjects in the
highest tertile of urinary tAs concentration carried a sig-
nificant higher risk of hypertension compared to those
in the lowest tertile before the adjustment (OR: 1.893,
95% CI: 1.219, 2.940), with a significant trend of increas-
ing hypertension risk along with increasing level of urin-
ary tAs concentration (p = 0.004). After the adjustment
for the confounders, although the association between
urinary tAs concentration and hypertension was not sig-
nificant (OR: 1.648, 95% CI: 0.999, 2.721), there was a
borderline-significance of 0.051. Moreover, the trend of
increasing hypertension risk along with increasing level
of tAs concentration remained significant (p = 0.046).
As for the urinary arsenic percentage, subjects in the
middle tertile of DMA% showed a significant decreasing
risk of hypertension compared to those in the lowest
tertile both before (OR: 0.596, 95% CI: 0.380, 0.935) and
after (OR: 0.548, 95% CI: 0.327, 0.920) the adjustment,
which indicated the association between DMA% and the
risk of hypertension.sure by partial correlation analysis






−0.017 0.682 0.158 0.000
−0.009 0.827 0.149 0.000
−0.001 0.984 0.166 0.000
−0.007 0.868 0.176 0.000
−0.021 0.605 0.081 0.490
−0.008 0.849 0.022 0.585
0.022 0.585 −0.040 0.327
and BMI.
Table 4 Crude and adjusted odds ratio (95%CI) of hypertension by urinary arsenic species and percentage
Tertile Test for trend
Urinary arsenic species
iAs (μg/g Cr) <7.31 7.31 to 33.68 >33.68
Hypertension (no/yes) 150/51 148/54 138/63
Crude OR (95% CI) (1.0) 1.073 (0.688, 1.675) 1.343 (0.869, 2.076) p=0.182
Adjusted OR (95% CI) (1.0) 1.301 (0.772, 2.192) 1.591 (0.963, 2.628) p=0.070
MMA (μg/g Cr) <11.28 11.28 to 37.89 >37.89
Hypertension (no/yes) 154/47 151/50 131/71
Crude OR (95% CI) (1.0) 1.085 (0.687, 1.714) 1.776 (1.148, 2.746)* p=0.009
Adjusted OR (95% CI) (1.0) 0.956 (0.565, 1.617) 1.693 (1.028, 2.787)* p=0.033
DMA (μg/g Cr) <66.70 66.70 to 181.85 >181.85
Hypertension (no/yes) 156/45 148/54 132/69
Crude OR (95% CI) (1.0) 1.265 (0.802, 1.994) 1.812 (1.166, 2.817)* p=0.008
Adjusted OR (95% CI) (1.0) 1.118 (0.661, 1.891) 1.549 (0.938, 2.559) p=0.082
tAs (μg/g Cr) <93.77 93.77 to 250.61 >250.61
Hypertension (no/yes) 156/45 150/52 130/71
Crude OR (95% CI) (1.0) 1.202 (0.760, 1.899) 1.893 (1.219, 2.940)* p=0.004
Adjusted OR (95% CI) (1.0) 1.085 (0.641, 1.837) 1.648 (0.999, 2.721) p=0.046
Urinary arsenic percentage
iAs (%) <7.30 7.30 to 15.76 >15.76
Hypertension (no/yes) 141/60 155/47 140/61
Crude OR (95% CI) (1.0) 0.713 (0.457, 1.112) 1.024 (0.669, 1.568) p=0.911
Adjusted OR (95% CI) (1.0) 1.099 (0.653, 1.853) 1.483 (0.897, 2.453) p=0.125
MMA (%) <11.85 11.85 to 16.41 >16.41
Hypertension (no/yes) 141/60 152/50 143/58
Crude OR (95% CI) (1.0) 0.773 (0.498, 1.200) 0.953 (0.620, 1.464) p=0.824
Adjusted OR (95% CI) (1.0) 0.747 (0.446, 1.252) 0.985 (0.586, 1.655) p=0.958
DMA (%) <68.73 68.73 to 79.07 >79.07
Hypertension (no/yes) 138/63 158/43 140/62
Crude OR (95% CI) (1.0) 0.596 (0.380, 0.935)* 0.970 (0.636, 1.480) p=0.887
Adjusted OR (95% CI) (1.0) 0.548 (0.327, 0.920)* 0.697 (0.420, 1.156) p=0.152
Data were based on log-transformed values.
Cut points were determined by tertile of overall study participants.
Adjusted OR were odds ratio adjusted for gender, age, cigarette smoking, alcohol consumption and BMI.
* p<0.05.
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Logistic regression analysis of hypertension in the subpop-
ulation of 360 subjects by CAE showed a positive associ-
ation between CAE and hypertension (OR: 1.913, 95% CI:
1.147, 3.191, p = 0.013) in the univariate logistic model.
After the adjustment for gender, age, cigarette smoking,
alcohol consumption and BMI, although the association
was not significant (OR: 1.752, 95% CI: 0.992, 3.096), there
was a borderline-significance of 0.053 (Table 5). When
CAE was divided into categories by cut point of tertile,
significant association between CAE and hypertension was
found in the highest tertile of CAE > 0.35 mg/L-year in
both models before (OR: 1.858, 95% CI: 1.064, 3.244) andafter (OR: 1.871, 95% CI :1.022, 3.424) adjustment, with
significant trends of increasing hypertension risk in cor-
responding to increasing level of CAE (p value of trend
before adjustment: 0.026, p value of trend after adjust-
ment: 0.040) (Table 6).
Discussion
Tens of millions of people worldwide have been chronic-
ally exposed to arsenic-contaminated drinking water
with the arsenic concentrations exceeding the WHO
recommended level of 0.01 mg/L. Chronic environmen-
tal exposure to arsenic through drinking water is
reported to be possibly associated with the elevated risks
Table 5 Logistic regression analysis of hypertension in




Model I OR (95%CI) 1.913 (1.147, 3.191)
Model II OR (95%CI) 1.752 (0.992, 3.096)
Model I: Univariate logistic regression model.
Model II: Model was adjusted for gender, age, cigarette smoking, alcohol
consumption and BMI.
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Up to date, only a few cross-sectional and cohort studies,
mainly from Taiwan, Bangladesh and the United States,
have investigated the association between hypertension
and chronic arsenic exposure, however, it is still inconclu-
sive [15,16]. Most of the reports have discussed the associ-
ation from the point of view of arsenic concentration in
the drinking water or CAE, few involved arsenic speciation
into the discussion. In this study, we evaluated the poten-
tial association between environmental arsenic exposure
through drinking water and the prevalence of hyperten-
sion by analyzing not only CAE but also urinary arsenic
speciation, and provided data on arsenic exposure and
hypertension from mainland of China.
In this study, we did not find any significant differ-
ences of urinary arsenic percentage between subjects
with and without hypertension. The urinary concentra-
tion of arsenic species of iAs, MMA, DMA and tAs of
subjects with hypertension were significantly higher than
those of the subjects without hypertension. Besides, sig-
nificant positive correlations were found between the
concentration of urinary arsenic species (iAs, MMA,
DMA and tAs) and blood pressure (systolic and pulse
blood pressure). However, no significant differences were
found between urinary arsenic percentage and blood
pressure. These results suggested that the urinary con-
centration of arsenic species was associated with the
elevated blood pressure, which indicated the possible
role of arsenic in the development of arsenic-induced






CAE (mg/L-year) <0.10 0.10 to 0.3
Crude OR (95% CI) (1.0) 1.058(0.587, 1
Adjusted OR (95% CI) (1.0) 1.204(0.632, 2
Adjusted OR were odds ratio adjusted for gender, age, cigarette smoking, alcohol c
* p<0.05.Since the levels of urinary arsenic species were dependent
on the cumulative body burden of arsenic exposure, the
higher cumulative arsenic burden, the higher urinary ar-
senic species. Our further findings of the positive associ-
ation between CAE and hypertension in the subjects of
the highest tertile of CAE, and the positive trend of in-
creasing risk of hypertension in corresponding to increas-
ing level of CAE indicated that the cumulative arsenic
burden, which was demonstrated by urinary arsenic spe-
cies, was associated with hypertension, and that there was
a strong linkage between high level of CAE and the risk of
hypertension.
Among the urinary arsenic species of iAs, MMA,
DMA and tAs, we found that subjects with higher urin-
ary concentration of MMA tended to be liable to suffer
from hypertension with a significant dose-dependent
trend. Besides, subjects with lower percentage of urinary
DMA also showed an elevated susceptibility to hyper-
tension. Since DMA was the methylated metabolite of
MMA, lower percentage of DMA implied less production
of DMA from MMA, which resulted in MMA remaining
unmethylated and accumulated.
MMA, the intermediate metabolites of arsenic methy-
lation, is more reactive and toxic than the other arsenic
species, especially MMAIII. It has been reported that the
urinary level of MMAIII, which is the most toxic species
among identified metabolites of iAs, may serve as an in-
dicator to identify individuals with increased susceptibil-
ity to toxic and cancer-promoting effects of arsenicosis
[23]. Many researches including our previous studies in-
dicated that high concentration or percentage of MMA
in the urine was associated with arsenic-related skin
lesions and cancers [19,24-26]. Our findings in this study
suggested that higher concentration of urinary MMA
might be related to the increased susceptibility to hyper-
tension, one of the noncancerous diseases of arsenicosis.
The MMA detected in this study included both the tri-
valent and pentavalent forms. We couldn’t detect the
single concentration of MMAIII in the urine due to the
undeveloped analysis system in our laboratory. It is obvi-
ous that the higher concentration of MMA in the urine,ion in the subpopulation by CAE category





.905) 1.858(1.064, 3.244)* p=0.026
.292) 1.871(1.022, 3.424)* p=0.040
onsumption and BMI.
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lation pathway. Therefore, concentration of urinary
MMA could be considered as a marker of MMAIII
converted, although it is not direct. Our findings are
quite compatible with the Huang group’s study which
showed that subjects with hypertension had a higher
CAE and a higher percentage of urinary pentavalent
MMA (MMAV) than the subjects without hypertension
in the arsenicosis-hyperendemic areas in southwest of
Taiwan where residents stopped drinking the artesian
well water for 2 to 3 decades [12].
Since MMAIII is the most reactive and toxic metabolite
of arsenicals, recent studies have focused on the role of
it on the mechanisms of arsenic-related cancer and
noncancerous diseases. It has been reported that MMAIII
could induce smooth muscle dysfunction through the dis-
turbance of Ca2+ regulation, which resulted in impaired
vasoconstriction and aberrant blood pressure change [27].
Lim et al. further indicated that low concentrations of
MMAIII at nanomolar level could potentiate the agonist-
induced vasoconstriction through Rho-mediated Ca2+
sensitization, which was manifested in vivo as increased
pressor responses leading to dysregulation of normal
physiological hemodynamics [28]. Our pervious study also
found that MMAIII induced endothelial nitric oxide syn-
thase (eNOS) phosphorylation in the endothelial cells
which seemed to be an adaptive response at the early stage
of exposure, but finally acted as a potent inhibitor of
eNOS leading to disruption of eNOS bioactivity which
consequently resulted in decreased NO bioactivity [29].
All of these studies provided evidences for the role of
MMAIII in arsenic-associated cardiovascular disease of
hypertension.
Because the participants of this study were recruited
from a rural county in which residents almost had the
same occupation as farmers, similar socioeconomic sta-
tus and lifestyles, the variation among subjects of these
potential confounders is likely to be small. Whereas diet-
ary habits, such as salt intake and dietary pattern, might
have an effect on the result. The lack of data collection
on salt intake, which has been considered as a potential
cause of hypertension, was a limitation of this study.
Since low intake of calcium, animal protein, folate, and
fiber were reported to increase the susceptibility of
arsenic-related injuries [30], and some vitamins, espe-
cially folic acid, was found to act as the co-factors in the
methylation metabolism of arsenic leading to variation
of arsenic speciation between individuals due to different
intake value [31,32], absent data of nutrient intake might
also be a limitation of this study.
Another limitation of this study might be the unidenti-
fied gene polymorphisms involved in the metabolism
and clearance of arsenic. Polymorphisms in a number of
genes, including GSTO1 and GSTO2 from glutathione-S-transferase (GST) family which use glutathione as a re-
ducing agent to catalyze pentavalent arsenicals to trivalent
forms, GSTP1, GSTZ1, GSTM1, and GSTT1 of GSTs fam-
ily which involved in the xenobiotic metabolism and play a
role in the cellular response mechanism against oxidative
stress induced by arsenic, arsenic 3-methyltransferase
(AS3MT) which use S-adenosyl-methionine as a methyl
donor to produce MMA and DMA, and methylene-
tetrahydrofolate reductase (MTHFR) of one-carbon me-
tabolism pathway, have been reported to be associated
with the variation in arsenic methylation capacity
[33-35] and susceptibility to arsenic-related skin lesions
[36-38] and bladder cancer [39-42]. Since the role of
gene polymorphisms in arsenic-related hypertension
was rarely discussed which still need further research,
we could not completely exclude the possible relation-
ship between polymorphisms of these genes and suscep-
tibility to the arsenic-related hypertension.
Conclusions
Taken together, our findings suggested that arsenic ex-
posure, especially high level of CAE, was positively asso-
ciated with the prevalence of hypertension, and that
higher concentration of urinary MMA might be related
to the increased susceptibility to hypertension. Further
studies are needed to evaluate the effects of low level
arsenic exposure from drinking water on hypertension,
and the association in some special aspects such as
nutritional deficiencies and gene polymorphisms.
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